Harbin Jixianglong Biotech Co., Ltd. 2026-03-11 Health serious FDA
Health · FDA · Recall #FDA-D-0380-2026
Semaglutide, For Rx compounding use only, packaged in a) 1g, NDC 84385-106-01; b) 5g,… Recall
Issued March 11, 2026 · Harbin Jixianglong Biotech Co., Ltd.
In March 2026, Harbin Jixianglong Biotech Co., Ltd. recalled the Semaglutide, For Rx compounding use only, packaged in a) 1g, NDC 84385-106-01; b) 5g,…, a serious health recall reported by the FDA.
Compiled by Maya Ellison, RecallCheckr
What this means for you
CGMP Deviations This recall has been initiated due to failing to complete process validation and bacterial endotoxin method validation before distribution
What you should do
- 1 Stop using Semaglutide, For Rx compounding use only, packaged in a) 1g, NDC 84385-106-01; b) 5g,… right away.
- 2 Set it aside where it won't be used by mistake.
- 3 Contact Harbin Jixianglong Biotech Co., Ltd. to arrange your voluntary. See the official notice below for contact details.
- 4 Keep the product until your remedy is fully processed. You may need it.
Official remedy (Voluntary):
Recall details
- Brand
- Harbin Jixianglong Biotech Co., Ltd.
- Category
- Health
- Recall date
- March 11, 2026
- Units affected
- Not reported
- Sold at
- Nationwide within the United States
- Recall number
- FDA-D-0380-2026
- Made in
- China
- Issuing agency
- FDA
In context
- Harbin Jixianglong Biotech Co., Ltd. has 1 recall in our database.
- We're tracking 3,576 Health recalls in our database.
- This is the 356th Health recall we've logged in 2026.